Merck's Fosamax May Boost Cancer Risk: FDA Official
In the latest blow to Merck & Co. Inc. over Fosamax, a U.S. Food and Drug Administration official has said the popular osteoporosis treatment and other similar drugs may increase the...To view the full article, register now.
Already a subscriber? Click here to view full article